For income investors watching volatile market conditions, the comfort of a regular, reliable dividend is hard to overstate. But finding these kinds of shares isn't easy... Excessive yields, weak financials and variable payouts can all...
|Type||Buy / Hold / Sell|
|Year End 31st Dec||Unit||2017||2018||2019||2020||2021||2022E||2023E||CAGR / Avg|
|Diluted Normalised EPS|
|Op. Cashflow ps|
|Free Cashflow ps|
|Diluted Weighted Average Shares||m|
|Book Value ps|
|Leverage (ttm)||Total||- Intang||+ Pension|
|Cash / Assets|
Latest News & Insights for BMY
Shares in Bristol-myers Squibb Co (NYQ:BMY) are currently trading at 60.01 but the question for investors is how much the market chaos of 2020 will impact on its price. The answer comes down to judging whether Bristol-myers Squibb Co i...
The Bristol-myers Squibb Co (NYQ:BMY) share price is currently trading at 63.27. But to try and predict what the price will look like in the next 12 months and beyond, it's worth knowing its strengths and potential weaknesses. The good...
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. The Company’s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.
- Giovanni Caforio CHM (56)
- David Elkins CFO (52)
- Ann Powell CHO (55)
- Sandra Leung EVP (60)
- Christopher Boerner EVP (50)
- Samit Hirawat EVP (52)
- Elizabeth Mily EVP (53)
- Louis Schmukler EVP (65)
- Rupert Vessey EVP (56)
- Paul von Autenried SVP (59)
- Adam Dubow SVP (54)
- Karen Santiago SVP (50)
- Joseph Eid SVP (53)
- Theodore Samuels LED (66)
- Manuel Medina DRC (53)
- Peter Arduini IND (56)
- Julia Haller IND (66)
- Paula Price IND (60)
- Derica Rice IND (56)
- Gerald Storch IND (64)
- Karen Vousden IND (63)
- Phyllis Yale IND (63)
Latest News for BMY
Upcoming Events for BMY
Q2 2022 Bristol-Myers Squibb Co Earnings Call
Q2 2022 Bristol-Myers Squibb Co Earnings Release
Q3 2022 Bristol-Myers Squibb Co Earnings Call
Q3 2022 Bristol-Myers Squibb Co Earnings Release
As of Today at 07:04 UTC, shares in Bristol-Myers Squibb Co are trading at $75.96. This share price information is delayed by 15 minutes.
Shares in Bristol-Myers Squibb Co last closed at $75.96 and the price had moved by +15.88% over the past 365 days. In terms of relative price strength the Bristol-Myers Squibb Co share price has outperformed the S&P500 Index by +23.56% over the past year.
The overall consensus recommendation for Bristol-Myers Squibb Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Bristol-Myers Squibb Co dividend yield is 2.65% based on the trailing twelve month period.
Last year, Bristol-Myers Squibb Co paid a total dividend of $2.01, and it currently has a trailing dividend yield of 2.65%. We do not have any data on when Bristol-Myers Squibb Co is to next pay dividends.
We do not have data on when Bristol-Myers Squibb Co is to next pay dividends. The historic dividend yield on Bristol-Myers Squibb Co shares is currently 2.65%.
To buy shares in Bristol-Myers Squibb Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $75.96, shares in Bristol-Myers Squibb Co had a market capitalisation of $161.72bn.
Here are the trading details for Bristol-Myers Squibb Co:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: BMY
Based on an overall assessment of its quality, value and momentum Bristol-Myers Squibb Co is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Bristol-Myers Squibb Co is $79.40. That is 4.53% above the last closing price of $75.96.
Analysts covering Bristol-Myers Squibb Co currently have a consensus Earnings Per Share (EPS) forecast of $7.59 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bristol-Myers Squibb Co. Over the past six months, its share price has outperformed the S&P500 Index by +57.69%.
As of the last closing price of $75.96, shares in Bristol-Myers Squibb Co were trading +15.94% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bristol-Myers Squibb Co PE ratio based on its reported earnings over the past 12 months is 9.74. The shares last closed at $75.96.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bristol-Myers Squibb Co's management team is headed by:
- Giovanni Caforio - CHM
- David Elkins - CFO
- Ann Powell - CHO
- Sandra Leung - EVP
- Christopher Boerner - EVP
- Samit Hirawat - EVP
- Elizabeth Mily - EVP
- Louis Schmukler - EVP
- Rupert Vessey - EVP
- Paul von Autenried - SVP
- Adam Dubow - SVP
- Karen Santiago - SVP
- Joseph Eid - SVP
- Theodore Samuels - LED
- Manuel Medina - DRC
- Peter Arduini - IND
- Julia Haller - IND
- Paula Price - IND
- Derica Rice - IND
- Gerald Storch - IND
- Karen Vousden - IND
- Phyllis Yale - IND